A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus

NCT05856448 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

186

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG: GLPG3667
DRUG: Placebo

Sponsor

Lakefront Biotherapeutics NV